Stryker (NYSE:SYK) Downgraded to Hold Rating by Wall Street Zen

Stryker (NYSE:SYK) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC upped their price target on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research report on Friday. Robert W. Baird set a $437.00 price objective on Stryker in a report on Friday. Truist Financial lowered their target price on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research report on Thursday, December 18th. Evercore ISI set a $390.00 price target on Stryker in a research report on Monday, January 5th. Finally, The Goldman Sachs Group set a $399.00 price target on Stryker in a research note on Friday, January 9th. Twelve analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $426.95.

Stryker Price Performance

Shares of SYK opened at $369.39 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The stock has a market cap of $141.26 billion, a PE ratio of 43.97, a PEG ratio of 2.27 and a beta of 0.89. Stryker has a 12-month low of $329.16 and a 12-month high of $404.87. The business has a 50-day simple moving average of $359.40 and a two-hundred day simple moving average of $371.80.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.73% and a net margin of 12.92%.The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $4.01 earnings per share. Analysts anticipate that Stryker will post 13.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Stryker during the second quarter valued at about $26,000. Clayton Financial Group LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at about $26,000. United Financial Planning Group LLC bought a new stake in Stryker in the 3rd quarter valued at about $27,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker during the 2nd quarter worth approximately $28,000. Finally, Sachetta LLC boosted its holdings in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Q4 results beat estimates — adjusted EPS $4.47 vs. $4.40 consensus and revenue of $7.17B (organic growth ~11%), with management citing strong Mako adoption as a growth driver. SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
• Positive Sentiment: Company raised its full‑year profit forecast and reported record revenue (>$25B FY2025) with adjusted operating margin expansion — supports upside to earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analysts are raising targets and reiterating buy ratings — Needham bumped its price target to $454 and reiterated Buy, reinforcing broker support after the print. SYK: Stryker price target raised by Needham Stryker: Sustained Double‑Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: 2026 guidance: management expects 8.0%–9.5% organic sales growth and adjusted EPS $14.90–$15.10 (roughly in line with street consensus); guidance shows continued growth but is narrowly ranged. Stryker projects 8%–9.5% organic sales growth for 2026
• Neutral Sentiment: Operating performance detail — adjusted operating margin widened ~100 bps to 30.2% in Q4 and management emphasizes margin expansion and new product launches as 2026 drivers. Stryker reports 2025 operating results and 2026 outlook
• Negative Sentiment: Headwinds and risks flagged — analysts and the company note possible 2026 tariff pressures, regulatory and macro risks that could constrain upside; keep an eye on cost/price dynamics and geopolitics. Stryker: Sustained Double‑Digit Growth and Operating Leverage Support Buy Rating
• Negative Sentiment: Insider selling activity flagged in some data summaries — notable executive/insider sales were reported which some investors monitor as a negative signal (context and timing matter). Stryker Reports Strong Q4 and Full‑Year 2025 Results (Quiver summary)

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.